Phase 2 Ovarian Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older who have a good general level of physical functioning (rated 0 or 1 on a standard oncology scale, meaning fully active or able to carry out light activities)
• People with certain advanced or spread cancers, depending on which part of the trial they would be enrolled in — including hormone receptor-positive, HER2-negative breast cancer; ovarian, peritoneal, or fallopian tube cancer; endometrial cancer; or triple-negative breast cancer (TNBC) — where specific genetic features or prior treatment history may apply (confirm with trial site for which group applies)
• People whose cancer has a specific genetic change called CCNE1 amplification, for certain parts of the trial
• People with breast cancer who have previously been treated with a type of drug called a CDK4/6 inhibitor and hormone therapy, for certain parts of the trial
• People with ovarian, peritoneal, or fallopian tube cancer whose cancer has stopped responding to platinum-based chemotherapy, for certain parts of the trial
• People who have had no more than 2 prior chemotherapy treatments for advanced or spread disease (with some exceptions depending on cancer type and treatment history — confirm with trial site)
• People whose cancer can be measured on standard scans
• People with adequate blood counts and organ function
• People who are able to swallow capsules or tablets

Who may not be able to join:

• People who have received another experimental treatment or cancer therapy within the past 2 weeks, or within 5 half-lives of that drug (whichever is shorter) before the planned trial start date
• People who have previously been treated with a CDK2 inhibitor, a PKMYT1 inhibitor, or a WEE1 inhibitor (and for one specific group in the trial, prior treatment with a type of drug called a topoisomerase inhibitor is also not permitted)
• People who have had major surgery within 4 weeks before the planned trial start date
• People who have received radiation therapy for symptom relief within 7 days before the first dose of the trial treatment (unless otherwise specified)
• People who have active, spreading cancer in the brain or surrounding tissue (active brain metastases or leptomeningeal disease)
• People who still have significant side effects from previous cancer treatments that have not resolved
• People with clinically unstable heart function (confirm with trial site for specific details)
• People with an active or ongoing infection or disease that affects how the immune system works
• People currently taking certain medications that strongly or moderately affect how the body processes drugs (known as CYP3A4 inhibitors or inducers — confirm with trial site)
• People with another active cancer, unless it has been in remission for long enough and approval has been granted by the trial sponsor
• People who are pregnant, breastfeeding, or planning to breastfeed during the trial or within 6 months of the last dose of the trial treatment

Important: Always verify eligibility with the trial site directly before applying.